Steve Pet

Steve Pet is an associate in the Washington, DC office of Gibson Dunn and a member of the firm’s Antitrust and Competition Practice Group.

He advises clients on all aspects of antitrust law, with a particular focus on merger and non-merger investigations before the Federal Trade Commission and the Department of Justice. Steve also has experience with complex private and government antitrust litigation and regularly counsels clients on compliance issues, including Robinson-Patman Act issues. His antitrust experience spans a wide range of industries, including healthcare, pharmaceuticals, food & beverage, energy, transportation, and technology.

Steve has served in various leadership roles in the ABA’s Antitrust Section, including as Vice Chair of the Agriculture and Food Committee and, currently, as Vice Chair of the U.S. Comments & Policy Committee. Before law school, Steve was an Honors Paralegal at the Federal Trade Commission’s Bureau of Competition, where he worked at both the staff level and in the Bureau Director’s Office. Among other matters, Steve was actively involved in the FTC’s successful challenge to the proposed $3.5 billion merger of Sysco and U.S. Foods.

Steve received his law degree from the University of Virginia School of Law, where he graduated Order of the Coif and served on the Virginia Law Review. Steve earned a Bachelor of Arts degree summa cum laude from Hamilton College.

Representative matters include*

• Represented Amazon in securing the FTC’s unconditional approval of Amazon’s acquisition of One Medical
• Represented Pioneer Natural Resources in securing the FTC’s clearance of ExxonMobil’s $64.5 billion acquisition of Pioneer, which created the largest oil and gas producer in the Permian Basin
• Represent PepsiCo in FTC v. PepsiCo, Inc. (S.D.N.Y)
• Represented Arch Resources in securing unconditional approval of its multi-billion dollar merger with Consol Energy to form Core Natural Resources
• Represented Celgene in securing the FTC’s conditional approval of its $74 billion acquisition by Bristol-Myers Squibb
• Represent Boehringer Ingelheim in antitrust class actions involving alleged monopolization of certain markets based on FDA Orange Book listings
• Represented DaVita in securing the FTC’s conditional approval of its acquisition of the University of Utah’s dialysis business
• Represented Merck in securing global antitrust clearance for its acquisition of Prometheus Biosciences
• Represented General Electric in its acquisition of BK Medical
• Represented Zensho Holdings in its acquisition of Snowfox Group.
• Represented Arch Coal in proposed joint venture with Peabody Energy from initial investigation through Section Request and litigation against the FTC (E.D. Mo.)
• Represented shipping provider during extensive DOJ investigation of proposed acquisition of another shipping provider, securing unconditional clearance
• Represented large technology company in FTC 6(b) study on non-reportable acquisitions, and global food producer in FTC 6(b) study on supply chain disruptions 
• Represented generic pharmaceutical manufacturer in massive multi-district litigation brought by state attorneys general and numerous putative private plaintiff classes (E.D. Pa.)

*Includes matters handled prior to joining Gibson Dunn.

Steve is admitted to practice in the District of Columbia.

Capabilities

• Antitrust and Competition

Credentials

Education:

• University of Virginia - 2018 Juris Doctor
• Hamilton College - 2012 Bachelor of Arts

Admissions:

• District of Columbia Bar